Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
about
Comparative safety and tolerability of anti-VEGF therapy in age-related macular degenerationThe safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic reviewThe era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapyInfluence of eye biometrics and corneal micro-structure on noncontact tonometry.Acute sterile endophthalmitis following intravitreal bevacizumab: case series.The effect of intravitreal bevacizumab (Avastin) on ocular pulse amplitude in neovascular age-related macular degeneration.Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandlingRecent advances in the management of neovascular glaucoma.Regression of iris neovascularization after subconjunctival injection of bevacizumab.Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure.The ABCs of RVO: a review of retinal venous occlusion.Changes in Retinal Nerve Fiber Layer Thickness after Two Intravitreal Bevacizumab Injections for Wet Type Age-related Macular Degeneration.Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumabTwo or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study.Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.Deletion of miR-150 Exacerbates Retinal Vascular Overgrowth in High-Fat-Diet Induced Diabetic Mice.Vascular Endothelial Growth Factor-A Increases the Aqueous Humor Outflow Facility.Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-AnalysisPost-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study.Ocular decompression with cotton swabs lowers intraocular pressure elevation after intravitreal injectionTopical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMDThe Anti-VEGF Epidemic: What are the Implications for Glaucoma Services?Treatments for macular oedema following central retinal vein occlusion: systematic review.Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration.Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab.VEGF as a Paracrine Regulator of Conventional Outflow Facility.Ranibizumab for age-related macular degeneration.Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literaturePharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and Correlations.Complications of intravitreal injections in patients with diabetes.Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.Variations in Treatment Delivery for Patients with Neovascular AMD in the UK: Results from an Ophthalmology Trainee Clinical Research Network Study.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Recent perspectives on the delivery of biologics to back of the eye.
P2860
Q26852289-70E40BE6-C2D0-4C1B-AFE0-DDDD79DD73D5Q27013836-EC99E569-BB82-428B-899A-BB02EED67FA8Q28067341-DAB770FD-59C2-4CD7-937B-185BE1B31FC5Q33638194-A06BAF49-0569-4E91-880D-886C04A977B6Q34182273-DF6B39E7-8B7B-40C2-A979-D06CF7DA44DCQ34620930-8FE2EB80-B3F6-4523-B611-055C9CC619FFQ34645555-2E867F6B-0606-4BC5-9008-CFBE5B5320DDQ34734475-47A2367B-982C-4F12-BD83-733D1DD2C88BQ34889150-A386D89B-8C19-40E4-BC7D-0AE368D4E9C8Q34953629-FCA65A41-B808-434D-A218-393EC0C54A08Q35047634-EA9E296E-7777-4638-BE71-1ADA29798285Q35087028-B9758132-E9AF-44F7-BE95-44B011C45B3BQ35226694-82DC3C78-691D-4D86-B261-2B77D6CA4445Q35336651-7F2DD39E-8B03-45BD-8D28-C3143D815004Q35568276-912F2698-8FF6-4C60-A4E6-CB51D767C835Q35764068-5932918E-B578-4BF4-86A8-26BE2AF7BBFEQ35770567-0C1D06D2-775B-4DD9-9251-5F20850B79ABQ36053089-D42D031B-C304-4AEB-9311-799B0E02CEE6Q36120106-0E589A7E-09BA-4903-9AEB-8343FC578972Q36230124-A3D2C762-51C2-43FE-9ED3-33AE59E68FC5Q36468197-618C1937-4086-4112-AD95-223F90F63CDAQ36788545-8284F53F-94A6-472E-88DF-19F20D203021Q37161129-CA6D10DE-6B60-4AD7-AC16-E7DCB35675AEQ37166978-0DEC671A-7F9D-4AA0-8052-E47847A628E5Q37510708-D3700A8E-05D5-4BDB-8889-D6A3605CD77AQ37590692-CF666492-A06C-4B2A-B50E-18AA16033B9FQ37604259-F80EA700-9F47-49D2-AB68-6358CA3A81DCQ37708813-58F90655-65EB-4278-AB2B-61F93DBDF8A0Q37731916-68F9AF15-C784-47F9-A213-1B49874DBF54Q37981760-6E2C57F7-17DE-4437-A458-A73D9D81A978Q38062429-E9FBE90B-5648-497F-86C8-183FAD72945CQ38103031-7C6AE80F-E4C4-491F-B862-ADE92F4D16FDQ38110731-9428DCA9-162E-4D80-AB9F-C742B23BC316Q38183850-59315FFF-F5A2-4621-9810-7AA975F2D15AQ38258551-5203CC25-4686-4B53-8EC5-27ED367950DCQ38261106-9A21C868-D592-4C3F-9D01-37A1956A4FF0Q38402203-AF57E2CF-B713-46DB-8E23-3F2D18982356Q38604243-5504426C-B4C2-4B4C-9DD2-99137BA5734BQ38633532-F2992166-0FF4-4684-BB2D-78E3037CB3B5Q38940171-79CE342B-B596-40DC-B5E2-7E1251C9E7D7
P2860
Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Sustained elevation of intraoc ...... njections of anti-VEGF agents.
@ast
Sustained elevation of intraoc ...... njections of anti-VEGF agents.
@en
type
label
Sustained elevation of intraoc ...... njections of anti-VEGF agents.
@ast
Sustained elevation of intraoc ...... njections of anti-VEGF agents.
@en
prefLabel
Sustained elevation of intraoc ...... njections of anti-VEGF agents.
@ast
Sustained elevation of intraoc ...... njections of anti-VEGF agents.
@en
P2093
P356
P1476
Sustained elevation of intraoc ...... njections of anti-VEGF agents.
@en
P2093
Alan E Kimura
Malik Y Kahook
Naresh Mandava
Travis J Good
P304
P356
10.1136/BJO.2010.180729
P407
P577
2010-08-11T00:00:00Z